4.4 Article

Nonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma

Journal

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/dju408

Keywords

-

Categories

Funding

  1. Australia and New Zealand Banking Group Limited Trustees and Rigshospitalet, University Hospital of Copenhagen
  2. Cure Cancer Australia
  3. National Health and Medical Research Council of Australia (NHMRC)
  4. Cancer Research UK
  5. Wellcome Trust
  6. Consejo Nacional de Ciencia y Tecnologia of Mexico
  7. Dutch Cancer Society [UL 2012-5489]
  8. Swedish Research Council
  9. Swedish Cancer Society
  10. Nordic Cancer Union
  11. European Research Council
  12. Division of Cancer Epidemiology and Genetics, National Cancer Institute
  13. Spanish Ministry of Economy and Competitiveness
  14. Red Tematica de Investigacion del Cancer (RTICC)
  15. Consolider-Ingenio RNAREG Consortium
  16. NHMRC
  17. Cancer Institute NSW
  18. Cancer Council Queensland
  19. Melanoma Research Alliance
  20. Aase and Ejnar Danielsens fund
  21. MRC [MR/L01629X/1] Funding Source: UKRI
  22. Cancer Research UK [10589, 13031, 19167] Funding Source: researchfish
  23. Medical Research Council [MR/L01629X/1] Funding Source: researchfish

Ask authors/readers for more resources

Background: The shelterin complex protects chromosomal ends by regulating how the telomerase complex interacts with telomeres. Following the recent finding in familial melanoma of inactivating germline mutations in POT1, encoding a member of the shelterin complex, we searched for mutations in the other five components of the shelterin complex in melanoma families. Methods: Next-generation sequencing techniques were used to screen 510 melanoma families (with unknown genetic etiology) and control cohorts for mutations in shelterin complex encoding genes: ACD, TERF2IP, TERF1, TERF2, and TINF2. Maximum likelihood and LOD [logarithm (base 10) of odds] analyses were used. Mutation clustering was assessed with chi(2) and Fisher's exact tests. P values under .05 were considered statistically significant (one-tailed with Yates' correction). Results: Six families had mutations in ACD and four families carried TERF2IP variants, which included nonsense mutations in both genes (p.Q320X and p.R364X, respectively) and point mutations that cosegregated with melanoma. Of five distinct mutations in ACD, four clustered in the POT1 binding domain, including p.Q320X. This clustering of novel mutations in the POT1 binding domain of ACD was statistically higher (P = .005) in melanoma probands compared with population control individuals (n = 6785), as were all novel and rare variants in both ACD (P = .040) and TERF2IP (P = .022). Families carrying ACD and TERF2IP mutations were also enriched with other cancer types, suggesting that these variants also predispose to a broader spectrum of cancers than just melanoma. Novel mutations were also observed in TERF1, TERF2, and TINF2, but these were not convincingly associated with melanoma. Conclusions: Our findings add to the growing support for telomere dysregulation as a key process associated with melanoma susceptibility.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available